Content versus Label Claims in Cannabidiol (CBD)-Containing Products Obtained from Commercial Outlets in the State of Mississippi

Content versus Label Claims in Cannabidiol (CBD)-Containing Products Obtained from Commercial Outlets in the State of Mississippi / Bill J. Gurley, Timothy P. Murphy, Waseem Gul, Larry A. Walker, Mahmoud ElSohly. - (Journal of Dietary Supplements (2020) 20 May; p. 1-9).
- https://doi.org/10.1080/19390211.2020.1766634
_________________________________________________

Abstract

Products containing cannabidiol (CBD) are now available throughout the United States, but their quality is oftentimes questionable. The CBD and Δ9-tetrahydrocannabinol (THC) content of 25 commercially available hemp oil products, obtained throughout the state of Mississippi, was determined via gas chromatography/flame ionization detection (GC/FID). These products were also analyzed for the presence of synthetic cannabinoids using full scan gas chromatography/mass spectrometry (GC/MS). Analytical findings were compared to label claims for CBD content. Product label claims for CBD ranged from no claim to 500 mg per serving; however, marked variability was observed between actual CBD content and claimed quantities. Of the 25 products, only three were within ±20% of label claim. Fifteen were well below the stated claim for CBD; two exceed claims in excess of 50%; and 5 made no claims. In addition, THC content for three products exceeded the 0.3% legal limit. Furthermore, four products—primarily marketed for vaping—were adulterated with synthetic cannabinoids. From this small, but diverse, sampling of hemp-derived merchandise, it appears that most product label claims do not accurately reflect actual CBD content and are fraudulent in that regard. Moreover, products that exceed legal THC levels may jeopardize a consumer’s employment status (i.e. failed “drug test”), while those adulterated with synthetic cannabinoids may subject them to serious adverse health effects. These findings argue strongly for further development of current good manufacturing practices for CBD-containing products and their stringent enforcement.

Parameters

Science
Study
Date
20 May 2020
People
ElSohly, Mahmoud
Gul, Wassem
Gurley, Bill J.
Murphy, Timothy P.
Walker, Larry A.
Country
United States of America
Language
English
Other organisations
ElSohly Laboratories
University of Mississippi
Doping classes
S8. Cannabinoids
Substances
Cannabis (THC)
Various
Supplements
Document category
Abstract
Date generated
18 May 2020
Date of last modification
28 May 2020
Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin